Revolution Medicines, Inc.
RVMD· Nasdaq
Released Mar 2, 2021, after the close
10-K filed Mar 2, 2021, 61 days after period end · 0001564590-21-010276
| Metric | Q4 2020 | Q4 2019 |
|---|---|---|
| Revenue | $8.75M | $12.09M |
| Net Income | -$34.20M | -$14.60M |
| EPS Diluted | -$0.52 | -$6.48 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Revolution Medicines, Inc. · CIK 1628171 · Engraved from SEC EDGAR
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
ended Dec 31, 2020 · filed Mar 2, 2021 · 61 d after period end
6.1% from the close of Mar 2, 2021 to the close of Mar 3, 2021, the first after the release.